Clinical Takeaway
Cannabinoid formulations, particularly CBD-containing products, show measurable reductions in anxiety symptoms across multiple study designs, though effect sizes and optimal dosing remain inconsistent across trials. Evidence for Tourette syndrome is preliminary but suggests potential benefit for tic severity and associated anxiety. Clinicians should interpret these findings cautiously given heterogeneity in formulations, doses, and outcome measures across included studies.
#23 Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.
Citation: Raminelli Adrieli Oliveira et al.. Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-Analysis.. Cannabis and cannabinoid research. 2025. PMID: 40956670.
Design: 6 Journal: 1 N: 0 Recency: 2 Pop: 2 Human: 1 Risk: -2
This systematic review and meta-analysis addresses a critical gap in evidence-based medicine by synthesizing efficacy data across diverse cannabinoid formulations for anxiety disorders, enabling clinicians to make informed prescribing decisions as regulatory access expands globally. The quantitative synthesis of outcomes across different cannabinoid preparations and dosing regimens provides necessary guidance for standardizing treatment protocols in conditions where clinical evidence currently lags behind regulatory approval and patient demand. Given the expanding therapeutic use of cannabinoids despite incomplete evidence, this analysis directly informs risk-benefit assessment and helps prevent inappropriate prescribing while identifying where further rigorous trials are needed.
Quality Gate Alerts:
- Preclinical only
Abstract: Introduction: Cannabinoid formulations have been increasingly proposed as therapeutic potential options for anxiety disorders (ADs). Several countries have expanded regulatory frameworks facilitating access to these compounds due to their alleged therapeutic benefits, including their application in ADs. Given its public health significance, we evaluated existing evidence regarding the efficacy of different medical cannabinoids as interventions for ADs and related mental conditions. Methods: A comprehensive search was conducted in PubMed, Embase, PsycInfo, Web of Science, Scielo, and Lilacs databases. We included randomized controlled trials (RTCs) assessing the effects of various cannabinoid formulations on patients with ADs and related conditions. Distinct meta-analyses were performed for cannabinoid subtypes. Analyses were conducted using Jamovi software, relying on standardized mean difference (SMD) calculations of pre/post-intervention score changes for both intervention and control groups. Results: We incorporated 21 placebo-controlled RCTs, examining cannabinoid interventions in social anxiety disorder (SAD = 5), generalized anxiety disorder (GAD = 1), post-traumatic stress disorder (PTSD = 7), obsessive-compulsive disorder (OCD = 1), and Tourette syndrome (TS = 7). Data extraction indicated considerable heterogeneity across outcomes, including clinical symptoms, neuroimaging findings, well-being, psychosocial functioning, safety, and tolerability. In studies utilizing pure or enriched CBD, the meta-analytic measure indicated a nonsignificant difference (SMD = -0.40; 95% CI: -0.84/0.03). However, a subgroup analysis of pure CBD compounds yielded a moderate, statistically significant effect size (SMD: -0.61, 95% CI: -1.15/-0.07). For studies investigating pure or enriched delta-9-tetrahydrocannabinol (Δ9-THC), the meta-analytic measure was -0.65 (95% CI: -1.06/-0.24), suggesting a moderate, significant effect favoring Δ9-THC-dominant compounds. In meta-analyses
🧠 While this systematic review addresses an important clinical question about cannabinoid formulations for anxiety disorders and Tourette syndrome, practitioners should recognize that the evidence base remains heterogeneous, with substantial variation in cannabinoid ratios, dosing protocols, delivery methods, and study populations that limits direct clinical applicability. The therapeutic window between anxiolytic and anxiogenic effects of cannabinoids is narrow and poorly characterized, particularly regarding CBD versus THC ratios and individual patient factors like baseline anxiety severity, concurrent medications, and cannabis use history. Publication bias toward positive outcomes and the relative scarcity of long-term safety and efficacy data in this field warrant cautious interpretation of meta-analytic findings. Clinically, this research may justify considering cannabinoid-based treatments as adjunctive options for carefully selected patients with treatment-resistant anxiety or Tourette syndrome after standard interventions have been optimized, but only with explicit informed consent regarding limited evidence quality, individualized titration protocols, and close monitoring for paradoxical anxiety exacerb